Journal of Hepatology

Article	Citations
THU-192 Liver steatosis assessed by controlled attenuation parameter in patients with primary biliary cholangitis	2579
SAT-521 Impact of centre type on treatment and survival outcomes in hepatocellular carcinoma (HCC)	2056
FRI-247 Association of plasma magnesium with MASH and cirrhosis: combined data from multiple therapeutic trials including more than 10, 000 patients	2014
THU-457 Outcome of liver transplantation in patients with hepatocellular carcinoma previously treated with immune checkpoint inhibitorbased therapy-first results from an international multicenter regi	1791
OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: t	788
FRI-195 Genetically determined circulating protein biomarkers and risk of advanced fibrosis	687
WED-257 FibroScan compared to liver biopsy for accurately detecting recurrent hepatic steatosis and fibrosis after liver transplantation for metabolic dysfunction-associated steatohepatitis	672
WED-092 Hyperuricemia leads to early cognitive dysfunction and neuronal cell injury in bile-duct ligated rats	517
THU-447 Incidence and predictors of complications following percutaneous liver biopsy: a multicenter study	407
TOP-311-YI Subtypes of steatotic liver disease have differing clinical outcomes	396
WED-495 The impact of integration and decentralization of HBV services on enhancing the HBV care continuum: an interrupted time series	359
OS-004 Testing for hepatitis C virus infection in prisons in England: room for improvement	358
FRI-475-YI NADPH oxidase 1 inhibition as therapeutic strategy in hepatocellular carcinoma: insights from human-relevant models	352
WED-058-YI High shear stress induced PIEZO1 activation promotes cytoskeleton remodelling and a nuclear deformation develops pro-thrombotic microenvironment and contributes to portal hypertension	339
OS-111 Predictive genomic biomarkers for Atezolizumab plus Bevacizumab combination immunotherapy response in liver cancer: insights from the IMbrave150 trial	335
SAT-479-YI Lower frequency of PNPLA3 in african populations and divergent associations with hepatocellular carcinoma	325
THU-099-YI Small duct primary sclerosing cholangitis is not associated with a heightened risk of colorectal cancer compared to inflammatory bowel disease alone	310
THU-219 Inhibition of HSD17B13 by INI-822 phenocopies the hepatic lipidomic profile of humans with the protective allele	300
SAT-070 Argon plasma coagulation or endoscopic band ligation for gastric antral vascular ectasia: a randomized comparative analysis	296
THU-114 Alkaline phosphatase levels at 6 months as a predictor of response to ursodeoxycholic acid at 1 year in patients with primary biliary cholangitis	295
FRI-457 CXCL12 restricts hepatocellular carcinoma progression by shaping the tumor microenvironment in liver fibrosis	294
THU-040-YI Establishment of the irish hepatology nurses association: an association for nurses working in liver disease in Ireland	288
SAT-009 Increased prevalence of metabolic-alcohol liver disease in Europe and of metabolic dysfunction-associated steatotic liver disease in the Americas. Results of the global IMPROVEMENT study	280
WED-524-YI Multi-omics study of chronic liver diseases with rifaximin treatment	279
FRI-067 Impact of Farnesoid X receptor polymorphisms on prognosis in hepatocellular carcinoma	277

SAT-418 Prevalence of hepatitis C virus infection in a nursing home: a frequently overlooked submerged population	263
SAT-194 Effect of statin therapy in patients with obesity and cirrhosis secondary to metabolic dysfunction-associated steatotic liver disease (MASLD) on pre-liver transplant mortality	229
FRI-245 Longitudinal follow-up of Fib-4 in patients at risk of steatotic liver disease (SLD) receiving low-dose Methotrexate treatment (LDMTX): results from the CIRT randomized placebo-controlled Tria	229
THU-093 Biochemical response and liver stiffness variation over time predict liver-related events in patients with primary biliary cholangitis treated with Obeticholic acid	226
WED-483 Performance comparison of four hepatitis E antibodies detection methods	215
FRI-470 Deciphering the role of FXR in the rewiring of Treg polarization in hepatocellular carcinoma	211
SAT-041 Real-world evidence of magnesium isoglycyrrhizinate for perioperative protection against hepatic injury in patients undergoing hepatectomy	204
THU-405 Analysis of a decentralized model interdisciplinary for the elimination of HCV in vulnerable population in the province of Huelva (Spain). To continue advancing in the elimination of hepatitis	202
THU-087 Herpesvirus viremia-cause or consequence of ACLF? Higher prevalence of cytomegalovirus, Epstein-Barr virus and herpes simplex virus viremia in patients with acute-on-chronic liver failure	201
WED-439 Linkage of anti‐HCV reactive persons to HCV care and treatment services in Georgia	199
WED-548 Rifaximin-alpha acts through increased abundance of Lactobacillus spp. in murine models of chronic liver disease	198
FRI-258 No evidence for viral escape mutations in immunodominant HCV-specific CD4 T cell epitopes	196
FRI-260 Identification of hepatitis B virus epitopes presented by human leukocyte antigen A*11:01 as potential targets for immunotherapy	195
THU-270 HBV genotype association with response to xalnesiran in nucleos (t)ide analogue treated participants with chronic hepatitis B infection in the Piranga phase 2 platform study	194
OS-020 Reviewing the utility of genetic cholestasis testing in adults with cholestatic liver disease	194
OS-044 Liver sinusoidal endothelial cell BRD4 drives inflammatory angiocrine signaling in liver fibrosis	192
FRI-144 Abrogation of hepatic TRb action protects the liver from acute liver injury	187
THU-489 Disruption of receptor-interacting protein kinase 1 post-translational modifications in alcohol-associated liver disease	186
LBP-015 Comparison of endoscopic ultrasound portosystemic gradient with HVPG and direct porto-systemic pressure gradient measurements	185
FRI-166 Real-world evidence on clinical outcomes and microbiome changes after healthy donor stool transplantation as palliative therapy compared to best supportive care in patients with unstable decom	184
FRI-161 Single-cell RNA sequencing reveals a fundamental role of LCN2+ neutrophils in the innate immune response in drug-induced acute-on-chronic liver failure	180
OS-075 Dual plasma molecular adsorption system therapy in patients with acute-on-chronic liver failure: a non-randomized clustercontrolled study (PADSTONE)	180
WED-086 Clinical evaluation of multimarker algorithmic scores for detection of early stage hepatocellular carcinoma in high-risk liver patients	175
WED-153 A patient charter for hepatocellular carcinoma: a co-created community call for action on equitable access to early diagnosis and multidisciplinary care	175
SAT-113 The intratumoral microbiome in HCC and its impact on treatment response	172
WED-083 Role of Child-Turcotte-Pugh and ALBI scores in patients with non-cirrhotic hepatocellular carcinoma	172
WED-262 Prolonged cholestasis following hepatitis A : what lies beneath	171
FRI-247 In vitro characterization of elebsiran (VIR-2218), an investigational siRNA therapeutic targeting hepatitis B virus	168
SAT-367 UNITED study: results of the up-titration phase of an open label, multicenter, prospective study to characterize the pharmacokinetics and pharmacodynamics of trientine dihydrochloride and to i	168
SAT-162 Epidemiology and Risk factors for development of AKI-HRS based on the new consensus definition	166
THU-069 A composite score of PRO-C6 and platelet count is prognostic for liver-related outcomes in patients with chronic hepatitis C	164
FRI-044 Dynamic adaptations of CD8+γδ T cells in acute and chronic hepatitis E virus infection	162
TOP-072-YI Human cirrhotic ascites contains myeloid reprogrammed T-cells capable of enhancing peritoneal immune surveillance	159
WED-164 Cirrhotic patients with acute variceal bleeding and an indication for preemptive-TIPS: real-life results	158
FRI-036 Single nucleotide polymorphisms of the vitamin D receptor and their impact on vitamin D- and Interleukin-6 levels in liver cirrhosis and acute-on-chronic-liver failure	155
SAT-178 Quantitative measurements of prothrombin in patients with cirrhosis and ascites: a validation study	150
SAT-205 Dynopenia predicts mortality in patients with liver cirrhosis and hepatocellular carcinoma	150
TOP-508 Derivation and validation of a new donor risk score incorporating graft steatosis and donor diabetes mellitus	150
THU-133-YI Risk of hypoglycemia in people with cirrhosis without diabetes	149
FRI-062 Trained human bone marrow mesenchymal stem cells enhance immunoregulatory responses and alleviate ConA-induced acute liver failure	148
FRI-481 Feasibility and effectiveness of liver transplantation following immunotherapy in patients with hepatocellular carcinoma	145
THU-334 Cholestasis as a predictor of PSC in inflammatory bowel disease: insights from a romanian cohort study	144
FRI-328 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes	143
WED-121 Comparison of clinical characteristics, risk factors and prognosis of HCC patients with lean and non-lean MASLD undergoing surgical resection	143
THU-308-YI Long-term evaluation of controlled attenuation parameter for steatosis monitoring in autoimmune hepatitis	143
THU-178 Siglec-5 is a functional biomarker that contributes to poor prognosis in patients with liver cirrhosis	141
SAT-136-YI Identification of prognosis determining risk factors in outpatients with cirrhosis	141
WED-145 Morphomolecular proliferative disease and microvascular invasion characterize PET-CT positive hepatocellular carcinoma cases: a single-center pilot study	140
WED-367-YI Frequency and risk factors of fibrosis staging discrepancies between transient elastography and liver biopsy in patients with metabolic-associated steatotic liver disease: role of obesity a	138
WED-373 Agreement between hepatic histology and non-invasive methods and their ability to detect MASLD/MASH among morbidly obese patients undergoing bariatric surgery: an egyptian crosssectional study	137

SAT-436 Efficacy of Imeglimin in MASLD with type 2 diabetes: a multicenter study	135
SAT-417-YI Sex disparities in response to low-carb, high-fat diet in MASLD	135
FRI-407 Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD	135
WED-405 PRO-C4, a biomarker of perisinusoidal fibrosis, is related to cardiometabolic risk factors, steatosis, and liver stiffness	134
WED-490 Ultrasound-derived visceral adipose tissue: an easily obtainable adiposity index strongly associated with metabolic dysfunctionassociated steatotic liver disease and metabolic parameters	133
FRI-335 Therapeutic potential of a GHRH analog in experimental MASLD	132
FRI-010 Economic evaluation of biomarker-base surveillance for hepatocellular carcinoma in thai patients with compensated liver cirrhosis	129
TOP-016 Genetic determinants of hepatitis B surface antibody disappearance in Taiwan’s vaccinated generations: a genome- wide association study	125
THU-405 Impact of ultra processed foods on metabolic dysfunctionassociated steatotic liver disease: limitations of the NOVA classification	124
TOP-505 Evaluation of a non-invasive pathway for advanced fibrosis detection and liver-related outcomes prognosis in the general population from China, United Kingdom, and United States	123
FRI-024 Living with liver disease: patient and carer experiences in the United Kingdom	122
WED-279 No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/ Emtricitabine/Tenofovir Alafenamide	120
Submit your late-breaker abstract for the EASL Congress 2024 between 27 March - 10 April	119
The space of Mall confirmed in humans: A response to “Portal venous branches as an anatomic railroad for a gut-bile duct axis”	118
Dual effects of brown-fat activation limit hepatocellular carcinoma (HCC) progress in steatotic liver	117
The effects of a structured dietetics intervention in patients with non-alcoholic fatty liver disease	116
Automation of hepatitis C screening through electronic health record algorithm	115
The LIVERSCREEN project’s goal is to to establish a population-based screening programme for liver fibrosis utilising non-invasive markers	115
Portal venous branches as an anatomic railroad for a gut-bile duct-axis	115
Reply to: “A comment on `A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B’”	115
Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease	114
LBP-036 Final results from the phase 3 REGENERATE trial evaluating the effects of obeticholic acid in patients with pre-cirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis	114
Feasibility of a home-based, virtually-delivered, group exercise intervention in older patients with liver cancer (TELEX-Liver Cancer)	114
LBP-016 Carvedilol versus propranolol in the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis	114
Prevalence and predictors of HDV viremia in anti-HDV positive patients of the HEllenic multicenter ReAl-life CLInical Study (HERACLIS-HDV)	112
Viral like particle analysis shows changes with PPIs and may be more sensitive than metagenomics to study PPI modulation of virome in cirrhosis	111
Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm	111
Hepatitis C seroconversion rates among individuals with repeated testing-Georgia, 2017–2021	111
Micro-elimination of chronic hepatitis C virus in patients with psychiatric disorders: a multidisciplinary strategy in the outpatient mental health center	109
HBV infection reshapes host chromatin accessibility and affects choline and iron metabolism	108
Molecular epidemiology of hepatitis B virus and hepatitis delta virus coinfection in-Sudan	108
Oral antibiotic treatment protects mice against the development of diet-induced non-alcoholic fatty liver disease but not against diet-induced intestinal barrier dysfunction	107
Genetic modifiers of liver phenotypes in pediatric Wilson disease: liver biopsy and transient elastography based study	106
Effect of housing temperature on non-alcoholic fatty liver disease development in C57BL/6N mice	104
Temporal trajectory of the model for end-stage liver disease (MELD) score for prediction of mortality among patients with liver cirrhosis	103
Beneficial effect of cystic fibrosis transmembrane conductance regulator modulators on adults with cystic fibrosis liver disease	102
Causes of death by fibrosis stage in 959 biopsy-proven NAFLD patients	101
Acute liver failure due neonatal hemochromatosis: case with fatal outcome despite early diagnosis and treatment	101
Assessing progress towards achieving regional hepatitis B control goal-nationwide serosurvey among children, Uzbekistan, 2022	99
Sofosbuvir/Velpatasvir/Voxilaprevir for re-treatment in direct-acting antiviral experienced hepatitis C virus patients: a systematic review and meta-analysis	99
Outcomes between surgical resection and transarterial chemoembolization in patients with multifocal BCLC-A and Child-Pugh B	98
Alcohol use disorder in patients undergoing bariatric surgery is associated with a worse prognosis	98
Disclosures: commercial relationships	98
Inclusion of the fatty liver-associated variants in the clinical workup of patients: results of an eight years’ experience in a tertiary referral center with genotyping facility	97
Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study	97
Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis	97
Effectiveness and safety of conversion surgery for patients with initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitors: a real-world study	97
Eliminating viral hepatitis one island at a time-the Hainan experience	97
Gut-liver crosstalk in hepatocellular carcinoma and non-selective beta-blockers: is there a link?	96
Booster SARS-CoV-2 vaccination elicits robust antibody response to wild type but not Omicron subvariants BA.4/5 in patients with cirrhosis	96
The gut (and its microbiota)-liver axis in liver disease associated with alpha-1-antitrypsin deficiency	95
The anti-fibrotic efficacy of Adelmidrol depends in the level of hepatic PPAR gama	95
Influence of language barrier and cultural differences in hepatitis B disease knowledge in the chinese community of Barcelona	95
Production of reactive oxidant species and fatty acid uptake is increased in regulatory T-cells in autoimmune hepatitis, and associated with down-regulation of markers linked to suppressor function	95
Sarcopenia at listing for liver transplantation is a negative predictor for post-transplant survival, but not for graft survival	94
Circadian sleep-wake rhythms in non-alcoholic fatty liver disease	94
A new nuclear-erythroid-2-related factor 2 activator for the treatment of non-alcoholic steatohepatitis: evidence of metabolic and anti-fibroinflammatory effects in human precision cut liver slices	93
APRI+ALBI score is superior to Indocyanine Green (ICG) clearance and LiMAx test in the prediction of posthepatectomy liver failure-an international multicenter study of 14581 patients	92
Perturbation of rhythmicity of the circadian clock-oscillator in hepatic stellate cells is associated with liver fibrosis	92
Exploration of the lack of systematic surveillance for hepatocellular carcinoma for patients with non-alcoholic fatty liver disease	92
Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis	90
HBsAg kinetics at month 9 after analogue treatment discontinuation in chronic hepatitis B eAg (-) predicts long-term HBV control	88
HCV micro-elimination strategy in a tertiary hospital: identification of lost cases and linkage to care	87
An explainable artificial intelligence model for prediction of high-risk non-alcoholic steatohepatitis	86
Policy and implementation needs for hepatitis B birth dose in the WHO African region: a survey of national program managers	86
Assessment of hepatic fibrosis screening in primary care using the FIB-4 score, followed in second line by an ELF (Enhanced liver Fibrosis) test	86
Association of liver fibrosis and hypophosphatemia in treatment-naïve patients with chronic hepatitis B	86
Toll-like receptor 5 signalling mediates pro-inflammatory and fibrogenic responses in non-alcoholic steatohepatitis (NASH)	85
HDV genotypes have an impact on pegylated interferon therapy response and long-term liver disease related outcomes	84
Methodological challenges in studying immune-suppressive neutrophils in HCC models	84
A gene editing approach for chronic hepatitis B: elimination of hepatitis B virus in vivo by targeting cccDNA and integrated viral genomes with a sequence-specific ARCUS nuclease	83
The impact of HCV cure on glycemic indices in patients using glecaprevir/pibrentasvir from nationwide Taiwan HCV registry	82
WED-511 FIB-4 for identifying chronic liver disease patients requiring HCC surveillance	82
The PNPLA3 genotype is the main driver of weight gain after the hepatitis C cure	82
Register now for the EASL Liver Cancer Summit!	81
Erratum to ‘Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis’ [J Hepatol 83 (2025) 70–80]	80
Digital pathology using stain-free imaging indices allows direct prediction of all-cause mortality, hepatic decompensation and hepatocellular carcinoma development in patients with non-alcoholic fatty	80
Correspondence on “Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis”	80
JHEP at a glance (October 2024)	79
MetALD accounts for a large part of what we call MASLD!	79

Hepatocyte senescence is linked with extrahepatic organ injury, failure of regeneration and mortality in patients with acute indeterminate hepatitis	79
Reply to: ‘Exploring hepatocellular carcinoma risks in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe’	78
Rethinking methodology and data integrity in Mendelian randomization: Insights from air pollution and MASLD research	78
Sign up to EASL Campus: your open-access eLearning Hub	78
Reply to: “Oral bis-choline tetrathiomolybdate rapidly improves copper balance in patients with Wilson disease”	78
Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score	78
Reply to: “Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices”	77
Aberrant ubiquitination causing liver cancer: The ADRM1-ΔEx9- FBXW7 connection	77
Genomics on the road to functional cure of hepatitis B	77
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations	77
MASLD and breast cancer risk: The role of hepatocyte-derived exosomes	76
Evaluating pruritus and fatigue in patients with treatment-refractory primary biliary cholangitis	75
WED-347 Diagnosis of advanced liver fibrosis: the synergy of open data, synthetic data generation, CatBoost, and feature engineering	75
Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination	75
What’s next after the 2026 BCLC update?	75
LBP-040 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interimresults for 2 years from the ASSURE study	75
Multi-omics profiling of cholangiocytes reveals sex-specific chromatin state dynamics during hepatic cystogenesis in polycystic liver disease	74
Assembling a new model to interrogate human liver biliary diseases	73
Emergency granulopoiesis in decompensated cirrhosis: Mechanistic and therapeutic considerations	73
Thrombotic microangiopathy or rejection in first pig-to-human patient liver xenotransplantation	73
THU-113 Optimizing thiopurine therapy in autoimmune hepatitis (AIH): a multi-center study on monitoring metabolite profiles and co-therapy with allopurinol	72
SAT-324 Latent class analysis identifies three distinct patient phenotypes in primary sclerosing cholangitis: implications for clinical trial access and mental health screening	72
OS-028 Early readmission in high-income countries contributes towards lower mortality-results from CLEARED global study	72
TOP-439 Oxidized mitochondrial DNA released from injured hepatocytes drives macrophage STING activation in acute-on-chronic liver failure	71
WED-509-YI Impact of jaundice on outcomes in patients with cirrhosis and ascites and implications for the definition of further decompensation	71
WED-361-YI Central vagal dysfunction reshapes neutrophil and T cell immunity in hepatocellular carcinoma	71
OS-080-YI The spatial single-cell landscape in the hepatitis B virus/hepatitis D virus-coinfected human liver reveals spatially confined immunosuppressive virus-immune niches	70
FRI-368 Cytokeratin 19 expression stratifies outcomes with hepatic arterial infusion chemotherapy but not atezolizumab plus bevacizumab in advanced hepatocellular carcinoma	70
FRI-301 Setting-up a biliary niche-on-a-chip for the study of human liver disease-associated ductular reaction	70
WED-157 Application of EASL guidelines for the assessment of risk for MASLD-related advanced fibrosis in an outreach screening of underserved rural communities in central and northern Romania using he	70
FRI-367 Clinical relevance of conversion therapy after atezolizumab plus bevacizumab in hepatocellular carcinoma: a multicenter study	70
WED-204 DM-LRE score: gradient boosting machine (GBM)-based machine learning model in predicting liver-related events (LREs) in type 2 diabetes mellitus (T2DM)	69
TOP-469-YI Remote patient monitoring reduces liver-related hospital readmissions in patients with acutely decompensated cirrhosis	68
FRI-122 A Novel murine model of metabolic dysfunction-associated alcoholic liver disease (MetALD) for therapeutic drug evaluation	68
TOP-343-YI LSECtin delivered to hAPCs by functionalized nanoparticles ameliorates chronic liver damage in experimental cirrhosis	68
WED-075 Comparison of clinical care pathways for metabolic dysfunctionassociated steatotic liver disease (MASLD) in type 2 diabetes (T2D) in the dawn of effective pharmacological therapy	68
OS-069 Efficacy and safety of interferon combined with antiretroviral therapy in people with HIV/HBV co-infection: a prospective observational study	67
WED-337-YI Retinoids reprogram TREM2+ monocyte-derived macrophages toward a restorative phenotype via redox control to attenuate liver fibrosis	67
THU-463 Combining different non-invasive tests stratifies the risk of clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD)	67
FRI-298 Integrated multi-omics approaches reveal IL-33 as a central pathogenic factor and potential therapeutic target in autoimmune hepatitis	67
WED-006 Implementation of the ReLink-C strategy in hospitals in Spain (ReLink-C Observatory Spain)	66
FRI-197 Comparative efficacy of non-cirrhotic MASH treatments: an updated network meta-analysis of phase 2–3 candidates	66
TOP-566-YI Hepatitis B core–related antigen predicts immune-active transition in HBeAg-negative indeterminate chronic hepatitis B	66
THU-030 Impact of alternative VCTE diagnostic criteria on yearly prevalence estimates of MASLD and significant fibrosis	65
WED-556-YI Biochemical response to Elafibranor in primary biliary cholangitis (PBC): impact of prior second-line therapy exposure	64
SAT-040 Burden, trends and projections of cirrhosis in China and G20 countries: a comparative study based on the global burden of disease database 2023	64
THU-031 Clinical burden and risk stratification in metabolic dysfunction-associated steatohepatitis using Swedish real-world data	64
THU-029 Public health implications of metabolic dysfunction-associated steatotic liver disease based on global stepwise approach to surveillance data	64
SAT-026 Sociodemographic associations between increasing alcohol sales and new hospitalizations for alcohol-related hepatitis in Alberta, Canada	62
SAT-220 Comparing obesity related cancer incidence in metabolic dysfunction–associated steatotic liver disease patients undergoing pharmacologic versus bariatric interventions	62
WED-596 Suppressing HBsAg by hepatitis B immunoglobulins does not lead to functional cure and has no impact on NK cell, T cell and B cell phenotypes in patients with chronic hepatitis B	62
FRI-027 Gaps between guidelines and clinical practice in hepatitis B virus reactivation prevention in non-hepatology immunosuppressive care	62
FRI-172 Imaging of Fibroblast Activation Protein: AZD2389 demonstrates liver target occupancy in participants with advanced chronic liver disease	61
TOP-488 Occurrence of overt hepatic encephalopathy after TIPS in a European prospective cohort of patients with cirrhosis treated by covered TIPS in the 2020s: a EuroTIPS study	61
THU-038 Real-world epidemiology and clinical outcomes in MASLD: A 20-year nationwide analysis of over 23 million individuals in Taiwan’s national health insurance research database	61
THU-516 Sarcopenia predicts post-TIPS hepatic encephalopathy, and early hepatic encephalopathy predicts mortality: evidence from a multicentric cohort	61
WED-574 Hepatitis C electronic patient record flags: an opportunity to remove inaccuracies and re-engage lost to follow-up patients	61
SAT-029 Socio-economic deprivation is overrepresented in Australian cirrhosis patients seeking acute hospital-based care, suggesting disparities in utilisation of structured outpatient services	61
THU-008 Socioeconomic barriers to initiation of second-line therapy in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid	61
SAT-227 Transcriptomic analysis revealed distinct mechanisms underlying the synergistic effect of a fatty acid synthase inhibitor and resmetirom combination in LDL receptor knockout MASH mice	61
WED-602 Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level	61
FRI-205-YI Sodium-glucose co-transporter-2 inhibitors and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes	60
WED-029 Population-based hepatitis C screening and elimination program in Lithuania: may it affect the incidence of hepatocellular carcinoma?	60
SAT-637 Integrated model nurse clinic reduces adverse pregnancy outcomes of pregnant women with chronic hepatitis B	60
THU-481 Same session validation of a custom-built 22G with the commercial 25G system for EUS-guided portal pressure gradient measurement	59
FRI-046 RE-LIVE study (Re-Linkage to Pan-Viral hepatitis): interim results from a multicenter observational study on care engagement in chronic viral hepatitis	59
SAT-037 Excess mortality from cirrhosis by neighbourhood deprivation, aetiology, and clinical presentation: a Swedish register-based cohort study	59
FRI-021 An optimized in-hospital management model enhances linkage to care for non-hepatology HBV-infected patients: interim analysis of Hot Wave Project 2.0	59
TOP-437 Immune dysfunction assessed by neutrophil-to-lymphocyte ratio predicts mortality and infection in acute-on-chronic liver failure	58
SAT-301 Investigating the burden of illness in primary sclerosing cholangitis (PSC): a multinational study	58
FRI-141 Early real-world effectiveness of resmetirom in adults with metabolic dysfunction associated steatohepatitis and moderate-to-advanced fibrosis	58
TOP-032 Real-world data highlight gaps in hospital care and access to gastroenterologists or hepatologists in patients with acutely decompensated cirrhosis	58
SAT-172 GPR84 antagonism shifts liver macrophage polarization from M1 to M2, increases liver triiodothyronine, and improves cholesterol levels and hepatic steatosis in a high-fat diet metabolic dysfun	58
THU-253 Study of the prevalence of hereditary hemochromatosis (HFE) and secondary causes of hiperferritinemia in patients participating in a bloodletting programme	58
FRI-117 Increased serum concentration and hepatic expression of Fibroblast growth factor 19 suggests it is a potential diagnostic biomarker for alcohol-related hepatitis	58
FRI-331 Targeting DNA stress response as a synthetic lethal strategy for activated hepatic stellate cells	58
FRI-490 Fitness accountability in liver transplant (LT) candidates: a survey on exercising habits, barriers and facilitators	58
FRI-150-YI Adipose tissue insulin resistance is a marker and amajor driver of severe metabolic dysfunction associated steatohepatitis	58
FRI-378 Sequential therapy patterns and prognostic impact of first-line treatment response in unresectable hepatocellular carcinoma patients with failure of Atezolizumab plus Bevacizumab	57
LBP-026 Hepatic recompensation is associated with sustained transplant-free survival in primary biliary cholangitis decompensated cirrhosis: an international multicenter study from the Global-PBC stud	57
FRI-105-YI Exhaled breath condensate bile acid profile correlates with plasma bile acid profile in alcohol related liver diseases	57
SAT-403 Analysis of structured and unstructured data from a large electronic health record system identifies frequent pruritus and fatigue in patients with PSC	57
SAT-465 Assessing the effectiveness of an educational intervention to improve BASL bundle compliance and optimise care in the first 24 hours for patients with acute decompensation of cirrhosis in a di	57
FRI-135-YI Leucine-rich alpha-2-glycoprotein 1 turnover indicates impaired regenerative signaling in alcohol-associated hepatitis	57
SAT-528 CT-derived spleen volume combined with routine labs accurately differentiates PSVD from cirrhosis across global cohorts	56
WED-352 Collectin-11 of the lectin pathway mediates complementdependent hepatic ischemia-reperfusion injury in mice	56
WED-395-YI Extracellular matrix remodeling and gender dimorphism in the progression of primary sclerosing cholangitis to cholangiocarcinoma	56
FRI-314 Targeting TRIM54: a potential protective strategy against liver injury in cirrhosis	56
WED-538 Prefrailty and frailty predict hospitalisation in patients with cirrhosis	56
FRI-232 Imaging-detected immune-related adverse events and clinical outcomes during Atezolizumab–Bevacizumab therapy in unresectable hepatocellular carcinoma: a dual-center study	56
SAT-382 Utility of spleen stiffness measurement for the detection of esophageal varices in primary biliary cholangitis (PBC)	55
WED-269 A serum-based biomarker of type VI collagen degradation (C6M) is associated with increased risk of hepatocellular carcinoma development	55
FRI-339 Acetyl-CoA carboxylase 2 inhibition in hepatic stellate cells drives their activation and enhances liver fibrosis	55
THU-127-YI Non-invasive two-step triage reduces access delays to liver services for people with metabolic dysfunction-associated steatotic liver disease: a tertiary program evaluation	55
FRI-073 Digital pathology and multi-omic profiling in abstinent patients with alcohol-related decompensated cirrhosis shows significant degrees of fibrosis regression associated to clinical improvemen	55